Alluvi, known as BI 4744, offers a significant advance in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/